What are lifetime outcomes of anti–vascular endothelial growth factor treatment for neovascular age-related macular degeneration?
In this multistate model using real-world data, an estimated 12% of the sample retained driving visual acuity and 15% reading visual acuity in at least 1 eye over their mean remaining lifetime of 11 years. More injections and younger age at baseline were associated with better outcomes.
Good lifetime vision outcomes can be achieved with anti–vascular endothelial growth factor treatment in neovascular age-related macular degeneration with more injections and an earlier start, increasing the chances of good outcomes and highlighting the need to provide easy access to this treatment.
Neovascular age-related macular degeneration (nAMD), the largest single cause of irreversible severe vision loss in high-income countries, can now be treated with vascular endothelial growth factor (VEGF) inhibitors, but to our knowledge, no data on lifetime outcomes are available.
To determine visual acuity (VA) outcomes of anti-VEGF treatment for nAMD in both eyes for patients’ remaining lifetime.
Design, Setting, and Participants
Multistate modeling using real-world cohort data of 3192 patients with nAMD (>67 000 visits) treated in routine eye clinics in Australia, New Zealand, and Switzerland. Data were analyzed between 2007 and 2015.
Intravitreal anti-VEGF treatment at the treating physician’s discretion and prospective data collection in standardized registry.
Main Outcomes and Measures
Visual acuity in both eyes over the remaining lifetime.
For the mean remaining lifetime of 11 years, an estimated 12% (n = 371; 95% CI, 345-400) of the sample retained driving VA and an estimated 15% (n = 463; 95% CI, 434-495) reading VA in at least 1 eye. At that time, an estimated 82% of the sample (n = 2629; 95% CI, 2590-2660) had dropped out. Younger age at baseline and more injections during the first year of treatment were associated with better long-term outcomes.
Conclusions and Relevance
Anti-VEGF treatment was associated with preserved useful visual acuity in almost 20% of patients over their average remaining lifetime. More than 80% of patients will cease treatment over that time, having likely experienced a deterioration of vision beforehand. This is a remarkable outcome compared with outcomes without intervention, which lead to legal blindness within 3 years of disease onset in 80% of those affected. These findings underline the public health necessity of providing anti-VEGF treatment to persons in need.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Finger RP, Puth M, Schmid M, Barthelmes D, Guymer RH, Gillies M. Lifetime Outcomes of Anti–Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. Published online October 15, 2020. doi:10.1001/jamaophthalmol.2020.3989
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: